Edward Daly, MD
Internal Medicine · Natchez, MSNPI 1801837679
Payments from drug & device makers
Across 504 payments — averaging $21.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$3K
- Pfizer$941
- Johnson & Johnson$700
- Lilly USA, LLC$649
- Boehringer Ingelheim$648
- AbbVie$575
- plus $4K from 28 others
What the payments were for
- Consulting fees$3,00027%
- Food & beverage$7,82072%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 3 | $3,029 |
| Pfizer | 62 | $941 |
| Johnson & Johnson | 45 | $700 |
| Lilly USA, LLC | 42 | $649 |
| Boehringer Ingelheim | 37 | $648 |
| AbbVie(2 entities) | 45 | $575 |
| Merck | 36 | $519 |
| Astellas Pharma US Inc | 27 | $492 |
| Novo Nordisk | 26 | $471 |
| GSK | 29 | $466 |
| Amgen | 28 | $454 |
| Novartis | 31 | $445 |
| AstraZeneca | 28 | $420 |
| Sanofi-aventis U.S. LLC | 20 | $342 |
| Abbott | 7 | $122 |
| Teva Pharmaceuticals USA, Inc. | 6 | $109 |
| Avanir Pharmaceuticals, Inc. | 5 | $64 |
| Sanofi Pasteur Inc. | 3 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $51 |
| Tactile Systems Technology Inc | 1 | $48 |
| Amarin Pharma, Inc. | 2 | $41 |
| Biogen | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Dexcom, Inc. | 2 | $29 |
| Biocryst US Sales Co., LLC | 1 | $20 |
| CSL Behring | 1 | $18 |
| Gilead | 1 | $17 |
| Abiomed | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
| Medtronic | 1 | $13 |
| Braintree Laboratories, Inc. | 1 | $13 |
How this compares
$10,920 in reported general payments places this provider in the 95th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 99 | $104,786 |
| EliquisApixaban | 112 | $96,583 |
| JardianceEmpagliflozin | 57 | $58,225 |
| JanuviaSitagliptin Phosphate | 57 | $40,768 |
| XareltoRivaroxaban | 33 | $36,962 |
| TrulicityDulaglutide | 25 | $35,165 |
| MounjaroTirzepatide | 33 | $32,098 |
| LinzessLinaclotide | 27 | $18,020 |
| MyrbetriqMirabegron | 24 | $14,234 |
| FarxigaDapagliflozin Propanediol | 11 | $11,965 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $10,084 |
| TrintellixVortioxetine Hydrobromide | 17 | $8,611 |
| Pantoprazole Sodium | 442 | $6,490 |
| Levothyroxine Sodium | 657 | $6,480 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $5,791 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $471 | $104,78699 claims |
| PfizerEliquis, Premarin | $941 | $101,495129 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat | $648 | $69,44680 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $649 | $67,26458 claims |
| MerckJanuvia | $519 | $40,76857 claims |
| Johnson & JohnsonXarelto | $700 | $36,96233 claims |
| AbbVieLinzess, Synthroid | $575 | $23,26999 claims |
| Astellas Pharma US IncMyrbetriq | $492 | $14,23424 claims |
| AstraZenecaFarxiga | $420 | $11,96511 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $342 | $11,53728 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $51 | $8,61117 claims |
| GSKTrelegy Ellipta | $466 | $5,79111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Natchez
- Blane MireNatchez$8K
- Kenneth StubbsNatchez$8K
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
- Kelly WilkinsonJackson$183K
- Magdy Gorgi-MikhailBiloxi$157K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.